Semaglutide is a Glucagon-like peptide-1 (GLP-1) produced by the

gut. It increases insulin production, a hormone that lowers the blood

sugar level while inhibiting glucagon secretion, which is a hormone

that raises blood sugar, reduces appetite and energy intake while

delaying gastric emptying. It was first developed in 2012 as a longer-

acting option to Liraglutide. In 2017 this drug was approved as an

anti-diabetic medication used to treat type 2 diabetes and obesity.

In June 2021, it got approved for chronic weight management in

obese individuals with a (BMI) ≥ 30 kg/m2) or overweight (initial BMI

≥ 27 kg/m2) with at least one weight-related comorbidity.

Levocarnitine is an amino acid that benefits energy levels by

transporting fatty acids into the mitochondria, where they can be

used as energy. For this reason, many take carnitine as a weight-loss

supplement to help accelerate fat burning.

This GPL1 medication  reduces food intake by lowering

appetite, slows food digestion in the stomach, decrease body fat percentage,  

Weight loss, decreased cardiovascular outcomes in

patients with type 2 diabetes and cardiovascular disease plus 

Lowers HbA1c levels.

It Enhances the growth of β cells in the

pancreas.